Clinton Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Clinton Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-118,879	Closed	-$6.42M	–	543
2017 Q3	$6.42M	Buy	+118,879	New	+$6.98M	0.7%	37
2017 Q2	–	Sell	-9,178	Closed	-$360K	–	965
2017 Q1	$360K	Buy	+9,178	New	+$292K	0.02%	717

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return

Clinton Group's PTLA Position: Q4 2017 in Review

Clinton Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q4 2017, closing a stake of 118,879 shares — an estimated $6.42M sold.

Clinton Group first reported a position in PTLA in Q1 2017 and held it in 2 quarters. The position peaked at $6.42M in Q3 2017. 215 funds tracked by Wall St. Rank hold PTLA as of Q4 2017.

Clinton Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Clinton Group sold 118,879 Portola Pharmaceuticals, Inc. shares in Q4 2017, an estimated $6.42M.
Clinton Group first reported a position in Portola Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
Clinton Group's Portola Pharmaceuticals, Inc. position peaked at $6.42M in Q3 2017.
215 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q4 2017.

Based on Clinton Group's 13F filing for Q4 2017, filed 14 Feb 2018.